https://orcid.org/0000-0002-9574-2685
Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yufeng Du, Chunhong Li & Jinsong Yan. (2023) The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis. Hematology 28:1.
Read now
Read now
Razwana Khanam, Moazzam Shahzad, Sibgha Gull Chaudhary, Fatima Ali, Zunairah Shah, Pranali S. Pachika, Zahoor Ahmed, Asmi Chattaraj, Adeel Masood, Nausheen Ahmed, Rajat Bansal, Ramesh Balusu, Leyla Shune, Faiz Anwar, Peiman Hematti, Joseph P. McGuirk, Abdulraheem Yacoub & Muhammad Umair Mushtaq. (2022) Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis. Leukemia & Lymphoma 63:11, pages 2671-2678.
Read now
Read now
Articles from other publishers (16)
Szymon Milnerowicz, Julia Maszewska, Paulina Skowera, Magdalena Stelmach & Monika Lejman. (2023) AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens. International Journal of Molecular Sciences 24:21, pages 15849.
Crossref
Crossref
Kenta Yamaoka, Masaki Fujiwara, Mayako Uchida, Yoshihiro Uesawa, Nobuyuki Muroi & Tadashi Shimizu. (2023) Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database. Oncology, pages 1-11.
Crossref
Crossref
Marion Gire, Émilie Chalayer & Élisabeth Daguenet. (2023) La place de l’IPA dans le suivi du patient âgé porteur d’une leucémie aiguë myéloïde. Soins 68:876, pages 26-29.
Crossref
Crossref
Phaedon D. Zavras, Ilias Sinanidis, Panagiotis Tsakiroglou & Theodoros Karantanos. (2023) Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. International Journal of Molecular Sciences 24:5, pages 5018.
Crossref
Crossref
Xiaoyan Hu, Lin Li, Jewel Nkwocha, Kanika Sharma, Liang Zhou & Steven Grant. (2023) Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells. Hematology Reports 15:1, pages 91-100.
Crossref
Crossref
Romeo G. Mihăilă. (2023) Venetoclax in Acute Myeloid Leukemia. Recent Patents on Anti-Cancer Drug Discovery 18:1, pages 11-28.
Crossref
Crossref
Stephen B. Baylin. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
13
.
Maiko Anzai, Takeo Yasu, Yoshito Gando, Mikio Shirota & Masayuki Kobayashi. (2022) Increased blood levels of venetoclax due to intake of crushed venetoclax tablets. Annals of Hematology 101:9, pages 2097-2098.
Crossref
Crossref
Mila S. Griffioen, David C. de Leeuw, Jeroen J. W. M. Janssen & Linda Smit. (2022) Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. Cancers 14:14, pages 3456.
Crossref
Crossref
Sankalp Arora, Carl Zainaldin, Srilakshmi Bathini, Udita Gupta, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D. Oliver, Donna Salzman, Antonio Di Stasi & Pankit Vachhani. (2022) Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia. Leukemia Research 117, pages 106844.
Crossref
Crossref
Georg Maschmeyer, Lars Bullinger, Carolina Garcia-Vidal, Raoul Herbrecht, Johan Maertens, Pierantonio Menna, Livio Pagano, Anne Thiebaut-Bertrand & Thierry Calandra. (2022) Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia 36:5, pages 1215-1226.
Crossref
Crossref
Raeseok Lee, Sung-Yeon Cho, Dong-Gun Lee, Hyeah Choi, Silvia Park, Byung-Sik Cho, Yoo-Jin Kim & Hee-Je Kim. (2021) Infections of Venetoclax-Based Chemotherapy in Acute Myeloid Leukemia: Rationale for Proper Antimicrobial Prophylaxis. Cancers 13:24, pages 6285.
Crossref
Crossref
Diana I Zamora, Gautami S Patel, Idan Grossmann, Kevin Rodriguez, Mridul Soni, Pranay K Joshi, Saawan C Patel, Devarashetty Shreya & Ibrahim Sange. (2021) Myelodysplastic Syndromes and Modalities of Treatment: An Updated Literature Review. Cureus.
Crossref
Crossref
Daniela Berger, Karin Bauer, Christoph Kornauth, Susanne Gamperl, Gabriele Stefanzl, Dubravka Smiljkovic, Christian Sillaber, Peter Bettelheim, Paul Knöbl, Ana-Iris Schiefer, Georg Greiner, Renate Thalhammer, Gregor Hoermann, Ilse Schwarzinger, Philipp B. Staber, Wolfgang R. Sperr & Peter Valent. (2021) Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. Neoplasia 23:12, pages 1183-1191.
Crossref
Crossref
Kazuya Sato, Nodoka Tsukada, Junki Inamura, Shigetsuna Komatsu, Keisuke Sato, Masayo Yamamoto, Motohiro Shindo, Kentaro Moriichi, Yusuke Mizukami, Mikihiro Fujiya, Yoshihiro Torimoto & Toshikatsu Okumura. (2021) Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine. Case Reports in Hematology 2021, pages 1-8.
Crossref
Crossref
Haruya Okamoto, Yuri Kamitsuji, Yukiko Komori, Nana Sasaki, Yasuhiko Tsutsumi, Akihiro Miyashita, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Tsutomu Kobayashi, Nobuhiko Uoshima & Junya Kuroda. (2021) Durable Remission of Chemotherapy-Refractory Myeloid Sarcoma by Azacitidine. The Tohoku Journal of Experimental Medicine 254:2, pages 101-105.
Crossref
Crossref